Q3 2023 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2023-11-14 · accession 0000950123-23-010736
$85.2M
Reported value
19
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $10.4M | 12.3% | 183,105 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $9.1M | 10.7% | 266,961 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $9.1M | 10.7% | 175,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $7.7M | 9.07% | 110,600 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $6.9M | 8.12% | 181,805 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $6.6M | 7.72% | 223,382 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $5.2M | 6.13% | 221,384 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $5.0M | 5.86% | 272,690 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $4.7M | 5.53% | 2,221,639 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $3.6M | 4.22% | 881,356 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $3.2M | 3.79% | 281,089 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $3.1M | 3.59% | 70,283 | Common | SOLE |
| 471871103 | — | JASPER THERAPEUTICS INC | $2.2M | 2.58% | 3,144,164 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $1.8M | 2.14% | 634,191 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $1.8M | 2.12% | 1,056,370 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $1.8M | 2.11% | 914,630 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.1M | 1.29% | 725,951 | Common | SOLE |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $1.1M | 1.24% | 531,915 | Common | SOLE |
| 58406B202 | MDVLQ | MEDAVAIL HOLDINGS INC | $707,382 | 0.83% | 117,897 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.